Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

MONTREAL, Oct. 21 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes. Data from the Phase 2 dose optimization study, which were used to determine the dose in the DEFEND trial, were presented at the International Diabetes Federation's 20th World Diabetes Congress currently taking place in Montreal, Canada.

In an oral presentation entitled "Otelixizumab - Dose regimen optimization of a humanized aglycosylated anti-CD3 monoclonal antibody in adult subjects with type 1 diabetes mellitus," Dr. Louis Vaickus, Chief Medical Officer at Tolerx, presented preliminary data from the Phase 2 otelixizumab dose optimization clinical study, referred to as TTEDD.

In a previous investigator-sponsored Phase 2 study, a high dose (48-64 mg) of otelixizumab was shown to preserve natural insulin production for up to 48 months after a single course of treatment. Subsequently, Tolerx initiated TTEDD to investigate alternative dosing regimens that would minimize adverse events, while maintaining durable clinical activity. A cumulative dose of 3.1 mg of otelixizumab administered over 8 days was identified as the optimized dose suitable for further evaluation. In TTEDD, this dosing regimen resulted in preservation of beta cell function (as measured by C-peptide, a common marker for endogenous insulin production) for up to 12 months in patients with autoimmune new-onset type 1 diabetes with no observation of significant safety issues.

About the DEFEND Study

DEFEND (Durable Response Therapy Evaluation
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results ... complete second quarter financial statements and MD&A have been filed on ... per shareThree-months ended , Six -months endedJune 30 , June 30 ... 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 , ...
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience technology company ... system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional and ... performance. Vision is the inception of every move ... or blocking a pass. The critical impact vision speed has ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... down the product choices to a manageable shortlist of bench and floor scales ... models that fit best with the customer’s industry and application. , Side-by-side ...
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... PRINCETON, N.J., Aug. 30 Medarex, Inc.,(Nasdaq: MEDX ... at the,Thomas Weisel Partners Healthcare Conference at 11:30 AM ... being held at the Four,Seasons Hotel in Boston, Massachusetts. ... for replay through the Webcast page in,the Investor Relations ...
... 30 Micromet, Inc.,(Nasdaq: MITI ), a ... antibody-based products for cancer, inflammation and,autoimmune diseases, today ... Officer of Micromet, will present at the Sal. ... Wednesday,September 5, 2007 at 9:50am Eastern time (3:50pm ...
... Mass., Aug. 29 Insulet Corporation,(Nasdaq: PODD ... Insulin,Management System, today announced that Duane DeSisto, Chief ... Healthcare,Conference. Mr. DeSisto is scheduled to present an ... on September 6, 2007 at The Four Seasons ...
Cached Biology Technology:Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007 2Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... virus in tissues from patients who died of a ... the strain of virus in the measles vaccine caused ... issue of The Journal of Infectious Diseases, now available ... many more cases of the disease, known as subacute ...
... emitted about as much carbon monoxide as did human-related ... time period, according to new research by the National ... atmospheric concentrations of ground-level ozone across much of the ... extent to which wildfires contribute to atmospheric pollution, was ...
... Abuse Deaths (np-SAD) based at the International Centre for Drug ... has been a decline in the number of drug-related deaths ... drop of eight per cent. The report published today ... by Coroners and Procurators Fiscal in the UK and Islands ...
Cached Biology News:New study shows measles immunization may prevent fatal brain infection 2NCAR analysis shows widespread pollution from 2004 wildfires 2Continued reduction in the number of drug-related deaths in the UK 2Continued reduction in the number of drug-related deaths in the UK 3
... Ek Adaptor encodes a T7 promoter, ... ATG translation initation codon, and an N-terminal ... 109 aa sequence that encodes thioredoxin. Fusion ... enhance solubility of many proteins that are ...
...
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
Biology Products: